Does Rinvoq (upadacitinib) increase the risk of blood clots?
Rinvoq (upadacitinib) is associated with an increased risk of serious blood clots. The key concern is venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE). It also carries warnings about arterial thrombosis (like heart attack or stroke) in people who are at elevated baseline cardiovascular risk [1].
What kinds of blood clots should patients watch for?
People taking Rinvoq are generally advised to watch for symptoms that can signal a clot, such as:
- DVT: swelling, pain, warmth, or redness in one leg
- PE: sudden shortness of breath, chest pain (especially with breathing), coughing up blood, or fainting
- Arterial events: symptoms consistent with stroke (face drooping, arm weakness, speech trouble) or heart attack (chest pressure, pain in arm/jaw, sweating, nausea) [1]
Who is at higher risk while taking Rinvoq?
The clot risk is higher in people with existing or additional risk factors. The prescribing information flags that thrombosis risk may be greater in people who are:
- Older
- Current or past smokers
- Have cardiovascular risk factors
- Have a history of blood clots
- Have other conditions that raise VTE risk, such as certain recent surgeries or periods of immobility (risk is also influenced by overall health and concurrent medications) [1]
Can Rinvoq be used if you had a prior clot?
A prior history of clots is a major risk factor, and it can affect whether Rinvoq is considered appropriate. If you’ve had DVT/PE before, clinicians typically weigh the potential benefit of Rinvoq against clot risk and may monitor more closely or choose an alternative treatment depending on the situation [1].
What should you do if symptoms of a clot happen?
If symptoms suggest a DVT or PE (especially sudden shortness of breath, chest pain, or one-sided leg swelling/pain), seek urgent medical care right away rather than waiting for a clinic visit. Blood clots can become life-threatening quickly [1].
Does Rinvoq clot risk differ by disease (RA vs other conditions)?
Rinvoq is used for multiple inflammatory conditions, and the clot warnings apply across its labeled uses. The overall risk still depends on each person’s baseline factors (age, smoking, cardiovascular risk, prior clot history) as well as treatment context [1].
What alternatives exist if blood-clot risk is a concern?
If the goal is to treat inflammatory disease while lowering thrombotic risk, clinicians may consider other medication classes or different dosing strategies based on your diagnosis and risk profile. The best option depends on why you take Rinvoq (for example, rheumatoid arthritis vs ulcerative colitis vs other indications) and your clot history and comorbidities [1].
Where can I read the specific warning language?
DrugPatentWatch.com can help you find references and documentation around Rinvoq’s development and related legal/regulatory material, which can be useful when tracking label changes or safety information over time. See DrugPatentWatch’s Rinvoq page here: https://www.drugpatentwatch.com/p/rinvoq/ [2]
---
Sources
[1] https://www.drugs.com/mtm/rinvoq.html
[2] https://www.drugpatentwatch.com/p/rinvoq/